David Shaw’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.7M | Sell |
36,040
-154,610
| -81% | -$9.93M | ﹤0.01% | 2944 |
|
|
2026
Q1 | $10.7M | Buy |
190,650
+59,173
| +45% | +$3.85M | 0.01% | 1575 |
|
|
2025
Q4 | $10.5M | Buy |
+131,477
| New | +$8.83M | 0.01% | 1702 |
|
|
2025
Q1 | – | Sell |
-18,237
| Closed | -$1.42M | – | 4439 |
|
|
2024
Q4 | $1.42M | Buy |
+18,237
| New | +$1.46M | ﹤0.01% | 2985 |
|
|
2024
Q3 | – | Sell |
-140,264
| Closed | -$11.6M | – | 4671 |
|
|
2024
Q2 | $11.6M | Buy |
140,264
+104,849
| +296% | +$9.22M | 0.01% | 1250 |
|
|
2024
Q1 | $3.02M | Buy |
35,415
+7,160
| +25% | +$562K | ﹤0.01% | 2293 |
|
|
2023
Q4 | $2.42M | Sell |
28,255
-1,153
| -4% | -$99.7K | ﹤0.01% | 2523 |
|
|
2023
Q3 | $2.63M | Buy |
29,408
+1,651
| +6% | +$147K | ﹤0.01% | 2360 |
|
|
2023
Q2 | $2.36M | Sell |
27,757
-82
| -0.3% | -$6.93K | ﹤0.01% | 2495 |
|
|
2023
Q1 | $2.3M | Buy |
+27,839
| New | +$2.25M | ﹤0.01% | 2589 |
|
|
2022
Q4 | – | Sell |
-7,998
| Closed | -$592K | – | 4957 |
|
|
2022
Q3 | $592K | Sell |
7,998
-32,820
| -80% | -$2.36M | ﹤0.01% | 3933 |
|
|
2022
Q2 | $2.66M | Sell |
40,818
-133,304
| -77% | -$7.89M | ﹤0.01% | 2816 |
|
|
2022
Q1 | $11M | Sell |
174,122
-16,589
| -9% | -$902K | 0.01% | 1518 |
|
|
2021
Q4 | $10.1M | Sell |
190,711
-68,911
| -27% | -$4.2M | 0.01% | 1655 |
|
|
2021
Q3 | $18.3M | Sell |
259,622
-256,145
| -50% | -$16.2M | 0.02% | 1078 |
|
|
2021
Q2 | $34.4M | Buy |
515,767
+399,381
| +343% | +$28.3M | 0.03% | 737 |
|
|
2021
Q1 | $12.9M | Buy |
116,386
+79,166
| +213% | +$9.8M | 0.01% | 1194 |
|
|
2020
Q4 | $4.42M | Sell |
37,220
-207,222
| -85% | -$22.3M | ﹤0.01% | 1965 |
|
|
2020
Q3 | $21.3M | Buy |
244,442
+129,566
| +113% | +$11.3M | 0.02% | 795 |
|
|
2020
Q2 | $10.3M | Buy |
114,876
+15,591
| +16% | +$1.57M | 0.01% | 1180 |
|
|
2020
Q1 | $9.89M | Sell |
99,285
-3,089
| -3% | -$335K | 0.02% | 1003 |
|
|
2019
Q4 | $11.8M | Buy |
102,374
+74,825
| +272% | +$9.05M | 0.01% | 1101 |
|
|
2019
Q3 | $3.48M | Sell |
27,549
-59,303
| -68% | -$7.53M | ﹤0.01% | 1921 |
|
|
2019
Q2 | $10.5M | Sell |
86,852
-183,756
| -68% | -$18.1M | 0.01% | 1109 |
|
|
2019
Q1 | $23.7M | Buy |
270,608
+31,037
| +13% | +$2.82M | 0.03% | 655 |
|
|
2018
Q4 | $24M | Sell |
239,571
-87,525
| -27% | -$9.19M | 0.03% | 626 |
|
|
2018
Q3 | $37.5M | Sell |
327,096
-70,225
| -18% | -$7.27M | 0.05% | 499 |
|
|
2018
Q2 | $35.6M | Buy |
397,321
+346,415
| +680% | +$29.3M | 0.05% | 472 |
|
|
2018
Q1 | $3.72M | Buy |
50,906
+30,398
| +148% | +$2.09M | 0.01% | 1601 |
|
|
2017
Q4 | $1.19M | Sell |
20,508
-88,930
| -81% | -$4.68M | ﹤0.01% | 2476 |
|
|
2017
Q3 | $4.91M | Buy |
109,438
+18,186
| +20% | +$756K | 0.01% | 1387 |
|
|
2017
Q2 | $3.6M | Buy |
91,252
+39,310
| +76% | +$1.61M | 0.01% | 1578 |
|
|
2017
Q1 | $2.11M | Sell |
51,942
-4,716
| -8% | -$184K | ﹤0.01% | 1810 |
|
|
2016
Q4 | $2.28M | Sell |
56,658
-62,480
| -52% | -$2.36M | ﹤0.01% | 1899 |
|
|
2016
Q3 | $4.31M | Sell |
119,138
-38,766
| -25% | -$1.33M | 0.01% | 1392 |
|
|
2016
Q2 | $4.58M | Buy |
157,904
+92,912
| +143% | +$2.81M | 0.01% | 1339 |
|
|
2016
Q1 | $2.27M | Buy |
64,992
+52,460
| +419% | +$1.69M | ﹤0.01% | 1796 |
|
|
2015
Q4 | $404K | Sell |
12,532
-40,624
| -76% | -$1.32M | ﹤0.01% | 3202 |
|
|
2015
Q3 | $1.72M | Buy |
+53,156
| New | +$2M | ﹤0.01% | 2206 |
|
|
2014
Q2 | – | Sell |
-13,351
| Closed | -$435K | – | 4333 |
|
|
2014
Q1 | $435K | Buy |
+13,351
| New | +$510K | ﹤0.01% | 3710 |
|
|
2013
Q4 | – | Sell |
-10,002
| Closed | -$399K | – | 4546 |
|
|
2013
Q3 | $399K | Sell |
10,002
-75,672
| -88% | -$3.17M | ﹤0.01% | 3737 |
|
|
2013
Q2 | $3.54M | Buy |
+85,674
| New | +$3.47M | 0.01% | 1616 |
|
Other funds holding HAE
AI
David Shaw's HAE Position: Q2 2026 in Review
David Shaw reduced its Haemonetics (HAE) stake by 81% in Q2 2026, selling an estimated $9.93M and leaving 36,040 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2944.
David Shaw first reported a position in HAE in Q2 2013 and has held it in 42 quarters since. The position peaked at $37.5M in Q3 2018. 327 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- David Shaw held 36,040 shares of Haemonetics worth $2.7M as of Q2 2026.
- David Shaw sold 154,610 Haemonetics shares in Q2 2026, an estimated $9.93M.
- Haemonetics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2944 holding.
- David Shaw first reported a position in Haemonetics in Q2 2013 and has held it in 42 quarters since.
- David Shaw's Haemonetics position peaked at $37.5M in Q3 2018.
- 327 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.